GenoMed, Inc. Establishes a Clinic for Preventive Molecular Medicine
ST. LOUIS, Nov. 20 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that it has established a clinic to deliver preventive molecular medicine in St. Louis.
Dr. David W. Moskowitz, GenoMed's Chairman and Chief Medical Officer will initially oversee the staffing of the clinic. The clinic will dispense GenoMed's proprietary treatments and diagnostic tests. Currently, two locations in St. Louis are available for immediate use.
Dr. Moskowitz commented, "GenoMed would prefer to train and certify physicians to participate in our Clinical Outcomes Improvement Program(TM). We would like patients to continue seeing their local physicians. However, patient demand is exceeding the ability of the Company to supply patients with GenoMed-certified physicians nearby. To make up for this short-fall in available physicians, which the Company hopes will be temporary, GenoMed has opened a clinic in St. Louis to see patients unwilling to wait any further."
Dr. Moskowitz continued, "Our patient outcomes have shown that the major benefit of our interventions, at least for kidney failure, come early in the disease process. After a certain point in kidney failure, our proprietary treatments are no better than conventional treatment. But in other diseases, such as emphysema, even a terminal patient may receive a significant benefit from our approach. It appears that for patients with diabetes or hypertension, there is little time to waste if one wants to delay the complications of these diseases."
Dr. Moskowitz concluded, "We anticipate receiving revenues from our Preventive Molecular Medicine Clinic within a few weeks, which will put us in the elite group of biotechnology companies with revenues."
About GenoMed
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease. A recent St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html ) reported that the company has applied for patents based on its finding that the ACE gene is associated with a large number of common, age-related diseases. The Company has filed patent applications on its new treatments for both human and veterinary use.
Consistent with the Company's goal to improve patient outcomes globally, GenoMed is currently working to license its treatments to physicians and healthcare systems worldwide.
For questions or appointments, please contact Krissy Fischer, tel. 1-877-GENOMED (1-877-436-6633), FAX 314-977-0042, email: kfischer@genomedics.com, or visit GenoMed at www.genomedics.com.
SOURCE GenoMed, Inc.
CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or
1-877-436-6633, or fax, +1-314-977-0042, or kfischer@genomedics.com/
Web site: genomedics.com
. |
